Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
NCT ID: NCT00137462
Last Updated: 2007-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
900 participants
INTERVENTIONAL
2004-11-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
torcetrapib/atorvastatin
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
Exclusion Criteria
* Intolerance to statin therapy
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Union Grove, Alabama, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Orange, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Golden, Colorado, United States
Pfizer Investigational Site
Bridgeport, Connecticut, United States
Pfizer Investigational Site
Fairfield, Connecticut, United States
Pfizer Investigational Site
Trumbull, Connecticut, United States
Pfizer Investigational Site
Waterbury, Connecticut, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Boynton Beach, Florida, United States
Pfizer Investigational Site
Fort Lauderdale, Florida, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Gainsville, Florida, United States
Pfizer Investigational Site
Sebastian, Florida, United States
Pfizer Investigational Site
Vero Beach, Florida, United States
Pfizer Investigational Site
Rockford, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Olathe, Kansas, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Burlington, Massachusetts, United States
Pfizer Investigational Site
Grand Rapids, Michigan, United States
Pfizer Investigational Site
Troy, Michigan, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Orchard Park, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Keizer, Oregon, United States
Pfizer Investigational Site
Salem, Oregon, United States
Pfizer Investigational Site
Doylestown, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Mt. Pleasant, South Carolina, United States
Pfizer Investigational Site
Mt. Pleasant, South Carolina, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Morristown, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
McKinney, Texas, United States
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Charlottetown, Prince Edward Island, Canada
Pfizer Investigational Site
Mirabel, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Saint Georges de Beauce, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5091019
Identifier Type: -
Identifier Source: org_study_id